News & Updates

In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.

In Singapore, about one in six children and young persons (CYPs) developed long COVID, with persistence of ≥1 symptoms 3 months after an acute COVID-19 infection, a survey study suggests.

In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.

Gut-brain interaction disorders and persistent gastrointestinal (GI) symptoms prevail 12–18 months following COVID-19 hospitalization, and these prolonged GI issues are associated with the severity of the symptoms during hospitalization and the psychological toll of the illness experience, according to a study.

During the COVID-19 lockdown period, major trauma cases such as road traffic accidents and worksite injuries have decreased while the opposite is true for interpersonal violence, which has shown a relative increase, according to a Singapore study.

Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.